MyMedR

Displaying all 3 publications

Abstract:

Sort:

Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B

Leow YW, Chan WK

J Viral Hepat, 2023 Aug;30(8):712.
PMID: 37337691 DOI: 10.1111/jvh.13858
LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease

Leow YW, Chan WL, Lai LL, Mustapha NRN, Mahadeva S, Quiambao R, et al.

J Gastroenterol Hepatol, 2024 Jul 01.
PMID: 38946405 DOI: 10.1111/jgh.16675

BACKGROUND AND AIM: LIVERSTAT is an artificial intelligence-based noninvasive test devised to screen for and provide risk stratification for metabolic dysfunction-associated fatty liver disease (MAFLD) by using simple blood biomarkers and anthropometric measurements. We aimed to study LIVERSTAT in patients with MAFLD and to explore its role for the diagnosis of advanced fibrosis.
METHODS: This is a retrospective study of data from MAFLD patients who underwent a liver biopsy. Patients with type 2 diabetes who underwent transient elastography and had liver stiffness measurement (LSM)
Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study

Leow YW, Chan WK, Goh GB, Wong VW, Fan JG, Kim YS, et al.

J Viral Hepat, 2023 Apr;30(4):319-326.
PMID: 36606597 DOI: 10.1111/jvh.13796

We aimed to compare the severity of liver disease, metabolic profile and cardiovascular disease (CVD) risk of chronic hepatitis B (CHB) patients with and without hepatic steatosis and patients with non-alcoholic fatty liver disease (NAFLD). Patients with NAFLD and CHB were prospectively enrolled from 10 Asian centres. Fibroscan was performed for all patients and hepatic steatosis was defined based on controlled attenuation parameter >248 dB/m. CVD risk was assessed using the Framingham risk score. The data for 1080 patients were analysed (67% NAFLD, 33% CHB). A high proportion (59%) of CHB patients had hepatic steatosis. There was a significant stepwise increase in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, controlled attenuation parameter and liver stiffness measurement, from CHB patients without hepatic steatosis to CHB patients with hepatic steatosis to NAFLD patients (p

Filters

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links